Percheron Therapeutics
- Short interest
- 0.02%
- −0.14 pp 30d
- as of 21 Feb 2025
- Reported shorts
- 237.1K
- Shares on issue
- 1.087B
Percheron Therapeutics (PER) Short Interest
Percheron Therapeutics (ASX:PER) had 0.02% of shares reported as short positions as of 21 Feb 2025, representing 237,138 shares. Percheron Therapeutics operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Percheron Therapeutics
The development of novel antisense pharmaceuticals for commercially important human conditions.
Company profile →Percheron Therapeutics (ASX:PER) has 0.02% of its shares on issue reported as short positions as of 21 Feb 2025, or about 237,138 shares. Over the past 30 days that figure has fallen 0.14 percentage points, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.16% in December 2024. PER is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads PER today
- Zanger BreakoutWatchScore 6rank 1921 of 1942
- CAN SLIMNot a candidate
- Minervini Trend TemplateWatchScore 7rank 1596 of 1716
- Crowded-Short BreakoutWatchScore 9rank 1173 of 1502
- Quality compoundersWatchScore 15rank 1009 of 1669
Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
PER fundamentals
In the year to 30 Jun 2026, Percheron Therapeutics (ASX:PER) recorded revenue of A$147.3K and a net loss after tax of A$4.8M. A year earlier it recorded revenue of A$371.1K and a net loss after tax of A$14.9M. Year-on-year growth: revenue −60.3% (FY). Net margin −3,253.9%, return on equity −54.7% (FY). Figures are in AUD, the company's reporting currency; source: ASX (Markit) and Yahoo Finance, as at 14 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest PER news
All news- Why Is Percheron Therapeutics (ASX:PER) Seeking Quotation for a Major New Share Issue?
kalkine · 13 Oct 2026
- Application for quotation of securities - PER
asx · 13 Oct 2026
- Application for quotation of securities - PER
asx · 13 Oct 2026
Company details
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss PER
Start a research thread or post the first pulse update